GRAIL INC

GRAIL’s Chief Growth Officer Sells 1,491 Shares to Cover Taxes—No Impact on Stock or Investor Sentiment

GRAIL insider sell‑to‑cover shows disciplined tax‑cover routine; investor confidence remains steady amid 49% annual gains and oncology pipeline buzz.

DirectorDealingsBot

06/06/2026, 02:31

2 minutes to read

CEO of GRAIL Inc. Buys Shares Amid 14% Weekly Decline, Hinting at Strong Trial Outlook

CEO Ofman’s June 1 buy signals confidence in GRAIL’s oncology platform and upcoming NHS‑Galleri trial—potential upside for investors.

DirectorDealingsBot

04/06/2026, 02:19

3 minutes to read

GRAIL Executives Trade Shares Amid Strong Clinical Momentum, Investors Urged to Watch Portfolio Moves

GRAIL insider trades reveal portfolio shifts, not panic—investors should watch CEO sales, new RSU awards, and strong Galleri trial results for long‑term growth signals.

DirectorDealingsBot

03/06/2026, 00:07

3 minutes to read

GRAIL CFO Freidin Aaron’s $49.92 Block Sale: Routine Tax‑Planning Move Amid Stock Volatility

GRAIL CFO Freidin Aaron sells 45,806 shares in April 2026: a routine tax‑cover move amid market volatility, not a bearish signal for investors.

DirectorDealingsBot

10/04/2026, 04:15

3 minutes to read

CEO’s $49.92 Block Sale at GRAIL: Tax Move or Warning Signal?

Investor alert: CEO Robert Ragusa’s $49.92 block sale of 123K GRAIL shares raises questions—tax‑covering or warning of short‑term volatility? Click to see what insiders mean.

DirectorDealingsBot

10/04/2026, 01:14

3 minutes to read

GRAIL Board Director Gregory Summe Buys $32k Worth of Shares via Deferred‑Stock Grant, Signaling Confidence in Company’s Future

GRAIL insider buys reveal board confidence: Summe’s 329‑share, $32k deferred‑stock grant signals long‑term value and a potential buying window amid market swings.

DirectorDealingsBot

16/01/2026, 23:17

3 minutes to read